Latest resource
Main deliverables
THE PARADIGM GAP ANALYSIS
Main deliverable
THE PARADIGM GAP ANALYSIS
D1.2 Criteria to assess how patient engagement expectations are met
D1.1 Survey analysis report on stakeholder-specific preferences, needs and expectations
Communications and External Engagement Plan
PARADIGM’s digital assets
Report on the first open Patient Engagement Forum
Report of the PARADIGM WP1 HTA Workshop on Early Dialogues held in London on 19th October 2018
HTAi and PARADIGM convened a workshop on the 19th October 2018 with HTA Agencies to discuss patient involvement in Early Dialogues.
Report of the Internal consultation on patient engagement sustainability
In June 2018, an internal consultation was organized by EURORDIS to explore with its members the different dimension of the sustainability of the patient engagement in medicines R&D.
Report for consultation with young persons: KidsBarcelona FSJD
Online survey may not be the most adequate method for understanding the views of some patient groups. Some patients may have some specific needs that have to be considered and addressed.
Consultation on Patient Engagement on development of medicines in dementia
PARADIGM WP1 aims to gain a better understanding of the needs, expectations and aspirations of the different stakeholders involved in patient engagement in the development of medicines and research.
D1.1 Survey analysis report on stakeholder-specific preferences, needs and expectations
To understand the needs, expectations and preferences from the perspective of different stakeholders, Work Package 1 (WP1) co-created with other WPs an online survey. The survey received 372 English language responses and 169 responses from 13 other European languages during the June and July in 2018. In addition to the survey, between June and October 2018, four different face-to-face consultations were carried out to involve the following vulnerable/ underrepresented and specific stakeholder groups : people with dementia, children and young 3 persons and people with rare diseases, as well as Health Technology Assessment (HTA) bodies.
PARADIGM at a glance
Meet the PARADIGM Consortium and get to know some interesting facts about them. PARADIGM’s mission is to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players.
PARADIGM Newsletter – 6 months of impact in patient engagement
Why yet another newsletter? Well, it's about creating a community as much as it is about communicating. We want to continue to build the base of participants in co-creating solutions to make patient engagement a greater reality.
PARADIGM One-pager 2018
PARADIGM’s objective is to develop much needed patient engagement processes and tools for three key decision-making points of the medicines development lifecycle: Research priority setting, Design of clinical trials and Early dialogue with regulators and HTA bodies.
Evolution of the Patient Engagement Ecosystem
Medicines lifecycle is critical to fostering patient access to innovative therapeutic solutions, and delivering better health outcomes for patients.
